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Background: Recent studies have shown that intake of n-3 polyunsaturated fatty acids (PUFAs) is associated with
reduced risk of cognitive impairment and coronary artery disease (CAD); however, it is currently unknown whether
reduced serum n-3 PUFA is associated with cognitive impairment in patients with CAD.
Methods: We retrospectively evaluated cognitive function with the mini-mental state examination (MMSE), serum levels
of PUFAs (including eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], dihomogammalinolenic acid [DGLA],
and arachidonic acid [AA]), cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, cerebrovascular
disease, and history of current/previous smoking), and parameters of cardiac function (left ventricular ejection fraction
and brain natriuretic peptide levels) in 146 Japanese CAD patients. The associations between the MMSE scores and the
other parameters were evaluated.
Results: Pearson correlation analysis showed that EPA (R = 0.25, P <0.01), EPA/AA ratio (R = 0.22, P = 0.01), and left
ventricular ejection fraction (R = 0.15, P = 0.04) were positively associated with MMSE score, and that age (R = −0.20,
P <0.01) and brain natriuretic peptide levels (R = −0.28, P <0.01) were inversely associated with MMSE score. Multiple
regression analysis showed that age (P <0.05) was negatively associated with MMSE score, while EPA (P <0.01) and
EPA/AA ratio (P <0.05) were positively associated with MMSE score; however, sex; body mass index; left ventricular
ejection fraction; levels of DHA, AA, and DGLA; DHA/AA ratio; brain natriuretic peptide; and presence of hypertension,
dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking were statistically
excluded.
Conclusions: Serum EPA concentration is associated with cognitive function in patients with CAD, suggesting that a
low serum EPA level is a risk factor for cognitive impairment independent of cardiac function, including left ventricular
ejection fraction. This correlation potentially lends further support to a role of dietary n-3 PUFAs in preventing the
cognitive decline in CAD patients.
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Table 1 Clinical characteristics of subjects
Variables
Number of patients 146
Mini-mental state examination score 27.8 ± 3.1
Male, n (%) 111 (76.0%)
Age, y 70.9 ± 8.6
Body mass index, kg/m2 23.5 ± 3.4
Systolic blood pressure, mmHg 127 ± 16.3
Diastolic blood pressure, mmHg 71 ± 11.6
Low-density lipoprotein cholesterol, mg/dL 96.0 ± 34.4
Triglycerides, mg/dL 124.5 ± 70.3
High-density lipoprotein cholesterol, mg/dL 55.0 ± 14.7
HbA1c, % 6.7 ± 5.5
Fasting plasma blood glucose, mg/dL 130.0 ± 58.7
Brain natriuretic peptide, pg/mL 151.6 ± 274.2
Left ventricular ejection fraction, % 58.6 ± 11.2
Fatty acids
Docosahexaenoic acid, μg/mL 132.5 ± 52.2
Eicosapentaenoic acid, μg/mL 68.9 ± 40.4
Arachidonic acid, μg/mL 173.0 ± 43.4
Dihomogammalinolenic acid, μg/mL 34.5 ± 11.4
Complications
Dyslipidemia, n (%) 126 (86.3%)
Hypertension, n (%) 131 (89.7%)
Diabetes mellitus, n (%) 80 (54.8%)
Cerebrovascular disease, n (%) 25 (17.1%)
Smoking, n (%) 108 (74.0%)
Drugs
ACEI/ARB, n (%) 91 (62.3%)
β-blockers, n (%) 53 (36.3%)
Calcium channel blockers, n (%) 62 (42.5%)
Statins, n (%) 123 (84.2%)
Ezetimibe, n (%) 8 (5.5%)
Diuretics loop, n (%) 27 (18.5%)
Mineralocorticoid antagonists, n (%) 7 (4.8%)
Unless indicated otherwise, data are presented as the mean ± standard
deviation.
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor
blockers.
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Cardiovascular disease has recently been implicated as a
major factor in the development of dementia, as these
diseases may be linked by shared common risks and
pathogenic elements [1,2]. Accumulation of cardiovascu-
lar risk factors therefore leads to cognitive impairment.
In addition, hypoxia/ischemia resulting from reduced
cerebral blood flow due to cardiac dysfunction may be
associated with dementia. Conversely, dementia itself
could be an independent cardiovascular risk factor;
patients with dementia have lifestyle-related problems,
such as inappropriate food or alcohol intake, sedentary
activity, and psychosocial stress, including depression
[3]. Therefore, the modification of these lifestyle-related
problems could be strategies for coronary artery disease
(CAD) and dementia prevention. While several pharma-
cological agents, including cholinesterase inhibitors [4],
have been developed for dementia, sufficiently effective
and curative treatments have not yet been established.
Therefore, the identification of residual risk factors is
important for dementia prevention.
The Japan Eicosapentaenoic Acid Lipid Intervention
Study showed that long-term use of eicosapentaenoic
acid (EPA) is effective for prevention of major coronary
events in Japanese hypercholesterolemic patients [5]. In
addition, recent studies demonstrated that consumption
of fish and n-3 polyunsaturated fatty acids (PUFAs)
reduced the incidence of cognitive impairment [6].
These studies indicate that a reduced serum level of n-3
PUFAs may be a risk factor for both CAD and cognitive
impairment.
However, it is currently unknown whether reduced
serum levels of n-3 PUFAs are associated with cognitive
impairment, and more specifically, which components of
PUFAs are associated with cognitive function in CAD
patients. Therefore, the aim of this study was to in-
vestigate the association between cognitive function and
n-3 PUFA levels (including eicosapentaenoic acid [EPA],
docosahexaenoic acid [DHA], dihomogammalinolenic
acid [DGLA], and arachidonic acid [AA]) in CAD pa-
tients, and to identify which components of PUFAs are
associated with cognitive function in these patients.
We hypothesized that decreased level of EPA would be
associated with cognitive impairment in patients with
CAD.
Material and methods
Patients and study design
In patients with CAD, serum PUFA levels were mea-
sured for identification of residual risk factors for CAD.
In addition, patients underwent mini-mental state exa-
minations (MMSE) to screen cognitive function [1]. We
retrospectively reviewed 146 consecutive Japanese patients
diagnosed with CAD in the Department of Cardiology atTokushima University Hospital between April 2013 and
March 2014.
Patients with CAD were defined as patients with a his-
tory of myocardial infarction, angiographic evidence of
at least 50% stenosis by area in at least 1 coronary artery,
evidence of exercise-induced ischemia, or history of
coronary revascularization. The exclusion criteria were
as follows: use of fish oil supplements or n-3 fatty acid-
containing drugs or a history of myocardial infarction
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active malignant diseases or liver dysfunction (aspartate
aminotransferase levels >100 IU/L, alanine aminotrans-
ferase levels >100 IU/L) were also excluded.
Hypertensive patients were defined as those with a
systolic blood pressure of ≥140 mmHg and/or diastolic
blood pressure of ≥90 mmHg and/or individuals recei-
ving antihypertensive medications. Dyslipidemic patients
were defined as those with a low-density lipoprotein
cholesterol level (LDL-C) of ≥140 mg/dL, a triglyceride
level of ≥150 mg/dL, a high-density lipoprotein cho-
lesterol level (HDL-C) of <40 mg/dL, or individuals re-
ceiving lipid-lowering medications. Diabetic patients
were defined as individuals receiving insulin or oral
hypoglycemic agents or those with an HbA1c level
of ≥6.5%, fasting plasma glucose level of 126 mg/dL, or
non-fasting plasma glucose level of ≥200 mg/dL.
Serum fatty acid composition, including levels of EPA,
DHA, DGLA, and AA, was measured by gas–liquidFigure 1 Distribution of levels of n-3 and n-6 polyunsaturated
fatty acids (PUFAs) stratified by age and sex. EPA, eicosapentaenoic
acid; DHA, docosahexaenoic acid; AA, arachidonic acid; DGLA,
dihomogammalinolenic acid.chromatography at a commercially available laboratory
(SRL, Tokyo, Japan).
Since n-6 PUFAs, including AA, are often considered
to be pro-inflammatory fatty acids and the EPA/AA ratio
is associated with a low incidence of cardiac events [7],
EPA/AA and DHA/AA ratios were also calculated.
In addition, other biochemical parameters, including
LDL-C, HDL-C, triglycerides, fasting plasma glucose,
and HbA1c, were also measured.
Cardiac function was evaluated by measuring brain
natriuretic peptide (BNP), a biomarker which represents
left ventricular endodiastolic pressure, and left ven-
tricular ejection fraction (LVEF) evaluated by echocar-
diography. The LVEF was calculated using the modified
Simpson's method with the apical 4-chamber and
2-chamber views.
Cognitive function was evaluated by MMSE, which is
widely used as a screening tool for assessment of cogni-
tive function [8].
This study protocol was approved by the Tokushima
University Hospital Ethics Committee.
Statistical analysis
Continuous variables were averaged and expressed as
the mean ± standard deviation, and categorical parame-
ters were expressed as a percentage. MMSE scores and
BNP levels were natural log transformed for statistical
analysis because of non-normal distributions. Associa-
tions between CAD risk factors and MMSE scores wereTable 2 Pearson correlation analysis between MMSE
scores and cardiovascular risk factors
Variables R P-value
Age −0.20 < 0.01
Sex - 0.30







Left ventricular ejection fraction 0.15 0.04
Brain natriuretic peptide −0.28 < 0.01
Hypertension - 0.96
Dyslipidemia - 0.89
Diabetes mellitus - 0.37
Cerebrovascular disease - 0.79
Current/previous smoker - 0.12
MMSE, mini-mental state examination; DHA, docosahexaenoic acid;
EPA, eicosapentaenoic acid; AA, arachidonic acid; DGLA, dihomogammalinolenic
acid.
Figure 2 Association between serum concentration of eicosapentaenoic acid (EPA) and EPA/arachidonic acid (AA) ratio and mini-mental
state examination (MMSE) score.
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relation analysis. Multiple regression analysis (standard
least squares method) was used to assess the degrees of
association between the CAD risk factor variables and
the MMSE scores. Residuals and residual vs. fit plots
were examined to ensure homoscedasticity.
All statistical analyses were performed using JMP 10
software. Statistical significance was defined as P <0.05.
Results
Clinical characteristics of subjects
Patient characteristics are shown in Table 1. The mean
MMSE score was 27.8 ± 3.1, indicating that subjects gen-
erally had mild cognitive impairment. The serum con-
centration of n-3 PUFAs, including EPA and DHA, and
n-6 PUFAs, including AA and DGLA, are shown in
Figure 1 by patient age and sex. EPA and DHA concen-
trations were the highest among patients aged ≥80 years,
and levels of EPA, DHA, DGLA, and AA were higher in
women than in men.
Correlation between n-3 PUFAs and MMSE score
The Pearson correlation analysis showed that levels of
EPA, EPA/AA ratio, and LVEF were positively associated
with MMSE score, and that age and BNP was inversely
associated with MMSE score (Table 2, Figure 2). There
were no relationships between MMSE score and body
mass index or levels of DHA, AA, DGLA, and DHA/AA
ratio (Figure 3). In addition, there were no differences in
MMSE scores according to patient sex and risk factors,Figure 3 There were no associations between serum concentration o
mini-mental state examination (MMSE) score.including hypertension, dyslipidemia, diabetes mellitus,
cerebrovascular disease, and history of current/previous
smoking. Interestingly, both LVEF and BNP (parameters
of cardiac function) were associated with serum levels
of DHA and DHA/AA but not EPA or EPA/AA
(Additional file 1: Tables S1 and S2).
Multiple regression analysis was then performed to
elucidate independent determinants of MMSE score; age
(P <0.05) was negatively associated with MMSE score,
while EPA levels (P <0.01) and EPA/AA ratio (P <0.05)
were positively associated with MMSE score. However,
sex; body mass index; levels of DHA, AA, DGLA, and
DHA/AA ratio; LVEF; levels of BNP; presence of hyper-
tension, dyslipidemia, diabetes mellitus, and cerebrovas-
cular disease; and history of current/previous smoking
were statistically excluded (Table 3).
Discussion
The present study demonstrated that decreased serum
levels of EPA and a reduced EPA/AA ratio are associated
with cognitive impairment in patients with CAD, indi-
cating that decreased EPA is a risk factor for develop-
ment of cognitive impairment this patient population.
AA levels showed no association with MMSE scores,
while low EPA levels were independently correlated with
MMSE scores. Therefore, EPA/AA did not increase the
predictive power of EPA alone. In addition, the Pearson
correlation analysis exhibited an association between
MMSE scores and LVEF or BNP; however, multiple re-
gression in an age-adjusted model showed no association.f docosahexaenoic acid (DHA) and DHA/AA ratio and
Table 3 Multiple regression analysis for determinants of
degree of MMSE score in patients with CAD




Age, years −0.004 −0.007 to −0.001 0.02
Male sex 0.005 −0.03 to 0.04 0.76
Body mass index, kg/m2 −0.0008 −0.001 to 0.007 0.85
Hypertension 0.02 −0.01 to 0.06 0.24
Dyslipidemia −0.001 −0.04 to 0.03 0.91
Diabetes mellitus 0.001 −0.02 to 0.02 0.98
Cerebrovascular disease −0.01 −0.04 to 0.02 0.50
Current/previous smoker 0.001 −0.03 to 0.04 0.80
EPA, μg/mL 0.001 0.0003 to 0.002 < 0.01
DHA, μg/mL −0.0004 −0.001 to 0.0003 0.22
AA, μg/mL 0.0001 −0.0001 to 0.001 0.83
DGLA, μg/mL 0.001 −0.002 to 0.004 0.45
LVEF, % 0.001 −0.001 to 0.004 0.20
BNP, pg/mL −0.015 −0.035 to 0.005 0.15
Model 2
Age, years −0.003 −0.006 to −0.0002 0.04
Male sex 0.002 −0.03 to 0.04 0.89
Body mass index, kg/m2 0.0008 −0.006 to 0.008 0.83
Hypertension 0.02 −0.02 to 0.05 0.37
Dyslipidemia 0.003 −0.03 to 0.04 0.84
Diabetes mellitus 0.002 −0.03 to 0.04 0.85
Cerebrovascular disease −0.01 −0.03 to 0.02 0.58
Current/previous smoker 0.003 −0.03 to 0.04 0.85
EPA/AA 0.15 0.03 to 0.28 0.01
DHA/AA −0.04 −0.15 to 0.07 0.42
LVEF, % 0.001 −0.001 to 0.003 0.29
BNP, pg/mL −0.018 −0.04 to 0.001 0.06
Model 1 R2 = 0.20; P <0.05.
Model 2 R2 = 0.17; P <0.05.
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; AA, arachidonic acid;
DGLA, dihomogammalinolenic acid; LVEF, left ventricular ejection fraction;
BNP, brain natriuretic peptide.
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cardiac function and age, our results indicate that MMSE
scores were associated with EPA levels independent of
cardiac function.
It has been reported that fish intake is associated with
cognitive function [9,10], and n-3 PUFA-containing food
improves cognitive function [11]. The exact mechanisms
of EPA on neuronal function are unknown; however, EPA
is involved in endothelial-dependent vascular function and
plays important roles in the prevention of microcircula-
tory insufficiency. Therefore, one possible mechanism is
that decreased EPA results in microcirculation insuffi-
ciency in the brain, thus leading to ischemia-induced braindamage. It has been reported that EPA enhances endo-
thelial expression of nitric oxide synthase, and activation
of endothelial nitric oxide synthase leads to vasodilation
and endothelial protection [12,13]. Reduced nitric oxide
synthase-induced microcirculation insufficiency may be
involved in the development of cognitive impairment.
Brain microvascular insufficiency, including cerebral white
matter disease, is an early marker of cognitive impairment
[14,15]. Thus, in patients with very mild cognitive impair-
ment, such as those who were included in this study,
microcirculation insufficiency rather than amyloid β de-
position, the cause of Alzheimer’s disease, may be the pre-
dominant contributor to vascular dementia.
It has been reported that vascular inflammation is asso-
ciated with cognitive function [16]. EPA is known to have
the ability to attenuate tumor necrosis factor-α-induced
upregulation of vascular cell adhesion molecule-1, in-
tercellular adhesion molecule-1, and monocyte chemo-
attractant protein-1 [17]. The anti-inflammatory effects of
EPA might contribute to the prevention of cognitive
impairment.
A previous meta-analysis demonstrated that subjects
with predementia syndrome had significantly lower
levels of EPA but not DHA or total n-3 PUFA [18]; thus,
serum EPA may be a more sensitive biomarker for
prediction of cognitive impairment compared to serum
DHA. It has also been reported that administration of
n-3 PUFA to patients with very mild Alzheimer’s disease
(MMSE >27 points) delayed the rate of cognitive dys-
function, indicating the importance of n-3 PUFA on brain
function in early stages of cognitive impairment [19].
In addition, EPA is converted into DHA in the liver
and at the blood-brain barrier and has been shown to
cross the blood-brain barrier after dietary supplementa-
tion, thereby suggesting that EPA plays important roles
in cognitive function after conversion into DHA [20,21].
EPA could be a rich source of DHA and may compen-
sate for reduced levels of DHA in the brain; decreased
serum EPA may thus be a more profound indicator of
cognitive function than decreased serum DHA.
The present study had several limitations. In parti-
cular, this was a retrospective study with a small sample
size in a single center. Larger clinical cohort studies
are needed to clarify the effects of EPA on cognitive
function.
Conclusions
Serum EPA concentration rather than serum DHA con-
centration is associated with cognitive function in pa-
tients with CAD, suggesting that a low serum EPA level
is a risk factor for cognitive impairment independent of
cardiac function. Our data support a role of dietary n-3
PUFAs in preventing the cognitive decline in CAD
patients.
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